An acromegaly case treated with clomiphene citrate: add-on treatment in primary medical therapy

Koroglu, Esma Pehlivan; Soyaltın, Utku Erdem; Yeral, Sena; YÜREKLİ, Banu SARER

doi:10.1007/s42000-022-00414-6

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, a 40-year-old man with uncontrolled acromegaly, despite maximal SRLs treatment and concurrent hypogonadism, was recently treated by adding CC 25 mg/day to standard therapy. After three months, the authors reported a complete normalization of IGF1 and testosterone levels, lasting two years [ 98 ].…”

Section: Clinical Use Of Estrogens And/or Serms In Patients With Acro...mentioning

confidence: 99%

Role of Estrogen and Estrogen Receptor in GH-Secreting Adenomas

Voltan

Mazzeo

Regazzo

et al. 2023

IJMS

View full text Add to dashboard Cite

Acromegaly is a rare disease with several systemic complications that may lead to increased overall morbidity and mortality. Despite several available treatments, ranging from transsphenoidal resection of GH-producing adenomas to different medical therapies, complete hormonal control is not achieved in some cases. Some decades ago, estrogens were first used to treat acromegaly, resulting in a significant decrease in IGF1 levels. However, due to the consequent side effects of the high dose utilized, this treatment was later abandoned. The evidence that estrogens are able to blunt GH activity also derives from the evidence that women with GH deficiency taking oral estro-progestins pills need higher doses of GH replacement therapy. In recent years, the role of estrogens and Selective Estrogens Receptor Modulators (SERMs) in acromegaly treatment has been re-evaluated, especially considering poor control of the disease under first- and second-line medical treatment. In this review, we analyze the state of the art concerning the impact of estrogen and SERMs on the GH/IGF1 axis, focusing on molecular pathways and the possible implications for acromegaly treatment.

show abstract

Section: Clinical Use Of Estrogens And/or Serms In Patients With Acro...mentioning

confidence: 99%

Role of Estrogen and Estrogen Receptor in GH-Secreting Adenomas

Voltan

Mazzeo

Regazzo

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Publishing on pituitary and adrenal diseases forms, of course, a major part of any journal dedicated to endocrinology. The present issue of Hormones contains highly interesting and important articles on growth hormone excess and acromegaly [16][17][18] and on adrenal diseases and their diagnoses [19][20][21][22].…”

mentioning

confidence: 99%

COVID-19, diabetes mellitus type 2, endocrine genetics, and pituitary and adrenal diseases

Stratakis

2023

Hormones

View full text Add to dashboard Cite

An acromegaly case treated with clomiphene citrate: add-on treatment in primary medical therapy

Cited by 2 publications

References 15 publications

Role of Estrogen and Estrogen Receptor in GH-Secreting Adenomas

Role of Estrogen and Estrogen Receptor in GH-Secreting Adenomas

COVID-19, diabetes mellitus type 2, endocrine genetics, and pituitary and adrenal diseases

Contact Info

Product

Resources

About